Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III, Single Arm, Open Label, International, Multi Centre Study to Evaluate the Efficacy and Safety of Lomitapide in Paediatric Patients With Homozygous Familial Hypercholesterolaemia (HoFH) on Stable Lipid Lowering Therapy

NCT04681170 is registered in ClinicalTrials.gov with Amryt Pharma as lead sponsor.

NCT NCT04681170
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04681170 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III, Single Arm, Open Label, International, Multi Centre Study to Evaluate the Efficacy and Safety of Lomitapide in Paediatric Patients With Homozygous Familial Hypercholesterolaemia (HoFH) on Stable Lipid Lowering Therapy
Lead sponsor
Amryt Pharma
Phase
Phase 3
Overall status
Completed
Start date
December 14, 2020
Completion date
June 6, 2024
Enrollment
46 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

homozygous familial hypercholesterolaemia (hofh)